Results 101 to 110 of about 1,923,383 (256)

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu   +4 more
wiley   +1 more source

Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities [PDF]

open access: yes, 2017
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical trials, particularly in B-cell malignancies. However, reports of serious adverse events including a number of patient deaths have raised concerns about safety ...
Wegner, A, Anja Wegner
core   +2 more sources

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025

open access: yesHuman Vaccines & Immunotherapeutics
CAR-T cell therapy has dramatically changed the treatment paradigm for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, there is a notable paucity of comprehensive bibliometric analyses within this specialized domain.
Tiantian Zhang   +4 more
doaj   +1 more source

Engineering better chimeric antigen receptor T cells

open access: yesExperimental Hematology & Oncology, 2020
CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with ...
Hao Zhang, Pu Zhao, He Huang
doaj   +1 more source

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

open access: yesJAMA Oncology, 2017
Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. Objective To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is ...
N. Ahmed   +32 more
semanticscholar   +1 more source

Efficacy and safety of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in hematologic malignancies: A living systematic review

open access: yes, 2023
This living systematic review aims to provide a timely, rigorous and continuously updated summary of the evidence available on the role of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for the treatment of patients with hematologic ...
Juan Erviti   +10 more
core   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui   +12 more
wiley   +1 more source

CAR-CD34 (+) hematopoietic stem/progenitor cells produced in vivo protect against thoracic aortic aneurysm and dissection

open access: yesNature Communications
Thoracic aortic aneurysm and dissection is one of the most devastating cardiovascular diseases, with limited medical intervention options. This study aims to develop chimeric antigen receptor-engineered CD34+ hematopoietic stem/progenitor cells and ...
Kaiwen Zhao   +12 more
doaj   +1 more source

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer

open access: yes, 2016
A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to ...
Miles H Prince (13534000)   +7 more
core  

Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields

open access: yesAdvanced Science, EarlyView.
Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng   +71 more
wiley   +1 more source

Home - About - Disclaimer - Privacy